Intra-Abdominal Infections, Respiratory Tract Infections, Sepsis, Skin and Soft Tissue Infection, Suspected Meningitis/Encephalitis or Any Other Infection, Urinary Tract Infections
Conditions
Keywords
Infection, mRNA, Procalcitonin, C-Reactive Protein, Lactate
Brief summary
This study will analyze gene expression and other laboratory data from biological samples collected from participants with suspected respiratory, urinary, intra-abdominal, and/or skin & soft tissue infections; or suspected sepsis of any cause.
Interventions
DIAGNOSTIC_TESTTriVerity
Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection and sputum/ BAL sample collection
Sponsors
Inflammatix
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age \>18 year 2. Suspected acute infection (respiratory, urinary, abdominal, skin & soft-tissue), and at least one of the symptoms OR, Suspected sepsis of any cause as defined by a blood culture order by the treating physician, and at least two of the symptoms: * Heart rate: \>90 beats/ minute * Temperature: \>38 C or \<36C * Respiratory Rate: \>20 breaths / minutes or PaO2 of \<60 mmHg or SpO2 \<90% * Systolic blood pressure: \<100 mmHg * Altered mental status: Per clinical exam 3. Able to provide informed consent, or consent by legally authorized representative.
Exclusion criteria
Participants will be ineligible for this study if they meet any of the following criteria: 1. Patient-reported treatment with systemic antibiotics, systemic antiviral agents or systemic antifungal agents within the past 7 days prior to the emergency department study visit. Participants will not be excluded for use of: 1. Antiviral treatment for HIV infection and hepatitis B and hepatitis C 2. Topical antibiotics, topical antiviral or topical antifungal agents 3. Anti-herpes prophylaxis aiding suppression of a recuring herpes infection 4. Peri-operative (prophylactic) antibiotics 5. A single dose of antimicrobials during the present ED visit (\<10h before blood draw); note single dose can be considered mono or combination therapy, wherein combination is administered as part of local Standard of Care and only one dose of each medication is administered within the allowable 10-hour window 2. Patients receiving palliative or hospice care, or those receiving limited interventional care. 3. Prisoners, mentally disabled, or unable to give consent. Should the patient not be able to provide informed consent the legally authorized representative can provide the consent on behalf of the patient. 4. Patients receiving experimental therapy or already enrolled in an interventional clinical trial in which a subject receives some type of intervention, which can include but is not limited to investigational drugs, medical devices, or vaccines. a. Subjects that are enrolled in non-interventional or observational clinical trials will be allowed to participate in this clinical trial. 5. Patients previously enrolled in the present clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the diagnostic performance of HostDx Sepsis | 28 Days After Enrollment | Concordance of HostDx Sepsis bacterial readout with clinical adjudication |
| Evaluation of the prognostic performance of HostDx Sepsis | 7 Days After Enrollment | Concordance of HostDx Sepsis severity readout with receipt of ICU-level care (including requirement for ICU transfer, mechanical ventilation, vasopressors, or renal replacement therapy (RRT)) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the prognostic performance of HostDx Sepsis | 28 Days after enrollment | Concordance of HostDx Sepsis severity readout with receipt of ICU-level care (including requirement for ICU transfer, mechanical ventilation, vasopressors, or renal replacement therapy (RRT)) within 7 days OR 28-Day Hospital Mortality |
| Evaluation of the prognostic performance of HostDx Sepsis for 28-Day Hospital Mortality | 28 Days after enrollment | Concordance of HostDx Sepsis severity readout with 28-Day Hospital Mortality |
Countries
Greece, United States
Outcome results
None listed